GMED Stock Analysis: Buy, Sell, or Hold?
GMED - GLOBUS MEDICAL INC
$90.68
0.46 (0.51%)
▲
BUY
MODERATE Confidence
Last Updated: January 30, 2026
Earnings: Feb 19, 2026
17d
Get Alerted When GMED Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
1 traders called GMED this week
100% bullish • 0 bearish
100% bullish • 0 bearish
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
💡 BUY OPPORTUNITY: GMED shows positive signals but monitor for confirmation. Market pricing in 0.3% decline. Moderate conviction.
💡 BUY OPPORTUNITY: GMED shows positive signals but monitor for confirmation. Market pricing in 0.3% decline. Moderate conviction.
Long-Term Wealth Forecast (2031)
Based on Analyst Consensus Growth & Historical Valuation
0% (Stagnation)
50% (Hyper Growth)
EST. PRICE IN 2031
$128.46
Based on 7.0% avg growth
INTRINSIC VALUE TODAY
$79.76
Trading above fair value
How this is calculated: We use a Growth Decay Model: starting with analyst consensus growth (adjusted above) and gradually slowing it down to a long-term terminal rate (4%) by Year 5. This provides a more realistic valuation than assuming constant hyper-growth. We then apply a 21.6x Exit PE.
In-depth Analysis How we analyze
Valuation Analysis: GMED is currently trading at $90.68, which is considered fair relative to its 30-day fair value range of $88.54 to $93.64. The stock's valuation (Forward PE: 21.4) is in line with its historical norms (21.6). Remarkably, the market is currently pricing in an annual earnings decline of 0.3% over the next few years. This pessimistic expectation contrasts with the company's recent 131.6% earnings growth, suggesting potential undervaluation if the company simply maintains stability.
Technical Outlook: Technically, GMED is in a strong uptrend. The price is currently testing key support at $89.33. A bounce from this level would confirm strength, while a break below could signal further downside.
Market Sentiment: The stock shows a mixed technical setup (40/100), with neutral trendline and momentum signals. Wall Street analysts see significant upside, with an average price target of $107.17 (+18.2%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Technical Outlook: Technically, GMED is in a strong uptrend. The price is currently testing key support at $89.33. A bounce from this level would confirm strength, while a break below could signal further downside.
Market Sentiment: The stock shows a mixed technical setup (40/100), with neutral trendline and momentum signals. Wall Street analysts see significant upside, with an average price target of $107.17 (+18.2%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Quick Decision Summary
Current Position
FAIR
Fair Price Range
$88.54 -
$93.64
Company Quality Score
50/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
70.0%
All Signals
- NEUTRAL: Price in fair range
- NEUTRAL: Mixed technical signals (40/100)
- BULLISH: High volume confirmation
- BULLISH: Trading below Wall St target ($107.17)
Fair Price Analysis
30-Day Fair Range
$88.54 -
$93.64
Current vs Fair Value
FAIR
Support & Resistance Levels
Support Level
$89.33
Resistance Level
$95.22
Current Trend
Strong Uptrend
Fundamental Context
Forward P/E (Next Year Est.)
21.36
Wall Street Target
$107.17
(+18.2%)
Revenue Growth (YoY)
22.9%
Earnings Growth (YoY)
131.6%
Profit Margin
15.3%
Valuation Discount vs History
-0.3% cheaper
PE vs Historical
21.4 vs 21.6
FAIR
Market-Implied Price Targets
If current PE multiple persists
Implied Growth (YoY):
-0.3%
(market-implied from PE analysis)
1-Year Target
$90.41
(0%)
2-Year Target
$90.14
(-1%)
3-Year Target
$89.87
(-1%)
3-Yr Target (if PE normalizes)
(PE: 21→22)
$90.86
(+0%)
3-Year Scenarios
Using analyst projected EPS growth
Bull:
(PE: 22.3, Growth: 10.0%)
$126.07
(+39%)
Base:
(SPY PE: 21.4, Growth: 10.0%)
$120.78
(+33%)
Bear:
(PE: 18.2, Growth: 10.0%)
$102.67
(+13%)
📈
Valuation based on Current Earnings
RECOVERY PLAY: Stock looks expensive now (30x PE), but valuation improves significantly next year (21x PE) as earnings recover.
Trailing PE: 29.72 | Current EPS (TTM): $3.09
Bull Case
$137.67
(+52%)
Analyst growth 36.3%, PE expands to 32.7
Base Case
$125.16
(+38%)
Market implied 36.3%, PE stable at 29.7
Bear Case
$62.44
(-31%)
Severe decline -20.0%, PE contracts to 25.3
These are projections based on PE multiples and EPS growth scenarios, not predictions. Actual results may vary significantly.
💡
Upside Surprise Potential
If earnings stabilize (0% growth), PE could expand from 21.4 to 21.6
Stabilization Target:
$91.68
(+1.1%)
PE Expansion Potential:
+1.1%
Last updated: February 01, 2026 3:43 PM ET
Data refreshes hourly during market hours. Next update: 4:43 PM
Data refreshes hourly during market hours. Next update: 4:43 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is GMED showing a specific setup today?
Insider Activity (6 Months)
0
Buys
1
Sells
Net
INSIDERS SELLING
Recent Transactions
Ann D Rhoads
SELL
10000 shares
2025-09-15
Top Rated Medical Devices Stocks
Top-rated stocks in Medical Devices by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
SYK
Stryker Corporation |
BUY
32 analysts |
$424 | 68 BUY |
|
DXCM
DexCom Inc |
STRONG BUY
26 analysts |
$85 | 65 BUY |
|
ABT
Abbott Laboratories |
BUY
28 analysts |
$134 | 63 BUY |
|
MDT
Medtronic PLC |
BUY
32 analysts |
$111 | 63 BUY |
|
EW
Edwards Lifesciences Corp |
HOLD
32 analysts |
$97 | 59 HOLD |
Advanced GMED Option Strategies
Professional options setups generated by AI based on today's GMED price and gamma walls.
